Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
复制标题
BNT162b2和mRNA-1273 covid-19疫苗在加拿大安大略省预防症状性SARS-CoV-2感染和严重covid-19结局的有效性：试验阴性设计研究
DOI：
10.1136/bmj.n1943
复制
发表时间：
2021-08-20
期刊：
影响因子：
--
通讯作者：
Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
中科院分区：
文献类型：
--
作者：
Chung H;He S;Nasreen S;Sundaram ME;Buchan SA;Wilson SE;Chen B;Calzavara A;Fell DB;Austin PC;Wilson K;Schwartz KL;Brown KA;Gubbay JB;Basta NE;Mahmud SM;Righolt CH;Svenson LW;MacDonald SE;Janjua NZ;Tadrous M;Kwong JC;Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
评估mRNA COVID-19疫苗对症状性感染和严重结局（住院或死亡）的有效性。测试阴性设计研究。于二零二零年十二月十四日至二零二一年四月十九日期间在加拿大安大略。324 033名年龄≥16岁的社区居民，他们有COVID-19症状并接受了SARS-CoV-2检测。BNT 162 b2（Pfizer-BioNTech）或mRNA-1273（Moderna）疫苗。实验室通过逆转录聚合酶链反应（RT-PCR）确认SARS-CoV-2，并与SARS-CoV-2感染相关的住院和死亡。多变量logistic回归分析调整了与SARS-CoV-2和疫苗接种相关的个人和临床特征，以估计疫苗对症状性感染和严重结局的有效性。在324033名有症状的人中，53270人（16.4%）对SARS-CoV-2呈阳性，21272人（6.6%）接受了至少一剂疫苗。在检测呈阳性的参与者中，2479人（4.7%）入院或死亡。一剂接种后≥14天观察到的疫苗对症状性感染的有效性为60%（95%置信区间为57%至64%），从一剂接种后14-20天的48%（41%至54%）增加至35-41天的71%（63%至78%）。两次接种后≥7天观察到的疫苗有效性为91%（89%-93%）。一剂接种后≥14天观察到的疫苗对住院或死亡的有效性为70%（60%至77%），从14-20天的62%（44%至75%）增加到≥35天的91%（73%至97%），而两剂接种后≥7天观察到的疫苗有效性为98%（88%至100%）。对于年龄≥70岁的成人，在一剂接种后不久的时间间隔内观察到疫苗有效性估计值较低，但在28天后的所有时间间隔内与年轻人的疫苗有效性估计值相当。在两次剂量后，观察到针对具有E484 K突变的变体的高疫苗有效性。据观察，两剂mRNA COVID-19疫苗对症状性感染和严重后果非常有效。据观察，一剂疫苗的有效性较低，特别是对第一剂疫苗接种后不久的老年人。
To estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death). Test negative design study. Ontario, Canada between 14 December 2020 and 19 April 2021. 324 033 community dwelling people aged ≥16 years who had symptoms of covid-19 and were tested for SARS-CoV-2. BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine. Laboratory confirmed SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) and hospital admissions and deaths associated with SARS-CoV-2 infection. Multivariable logistic regression was adjusted for personal and clinical characteristics associated with SARS-CoV-2 and vaccine receipt to estimate vaccine effectiveness against symptomatic infection and severe outcomes. Of 324 033 people with symptoms, 53 270 (16.4%) were positive for SARS-CoV-2 and 21 272 (6.6%) received at least one dose of vaccine. Among participants who tested positive, 2479 (4.7%) were admitted to hospital or died. Vaccine effectiveness against symptomatic infection observed ≥14 days after one dose was 60% (95% confidence interval 57% to 64%), increasing from 48% (41% to 54%) at 14-20 days after one dose to 71% (63% to 78%) at 35-41 days. Vaccine effectiveness observed ≥7 days after two doses was 91% (89% to 93%). Vaccine effectiveness against hospital admission or death observed ≥14 days after one dose was 70% (60% to 77%), increasing from 62% (44% to 75%) at 14-20 days to 91% (73% to 97%) at ≥35 days, whereas vaccine effectiveness observed ≥7 days after two doses was 98% (88% to 100%). For adults aged ≥70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days. After two doses, high vaccine effectiveness was observed against variants with the E484K mutation. Two doses of mRNA covid-19 vaccines were observed to be highly effective against symptomatic infection and severe outcomes. Vaccine effectiveness of one dose was observed to be lower, particularly for older adults shortly after the first dose.
登录
查看更多内容
影响因子：
5.5
作者：
Kwong, Jeffrey C.;Buchan, Sarah A.;Gubbay, Jonathan B.
通讯作者：
Gubbay, Jonathan B.
DOI：
10.1016/s1473-3099(21)00330-3
发表时间：
2021-11
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Hyams C;Marlow R;Maseko Z;King J;Ward L;Fox K;Heath R;Tuner A;Friedrich Z;Morrison L;Ruffino G;Antico R;Adegbite D;Szasz-Benczur Z;Garcia Gonzalez M;Oliver J;Danon L;Finn A
通讯作者：
Finn A
影响因子：
82.9
作者：
Chemaitelly, Hiam;Yassine, Hadi M.;Abu-Raddad, Laith J.
通讯作者：
Abu-Raddad, Laith J.
影响因子：
5.5
作者：
Jackson, Michael L.;Nelson, Jennifer C.
通讯作者：
Nelson, Jennifer C.
影响因子：
39.2
作者：
Butt, Adeel A.;Omer, Saad B.;Mayr, Florian B.
通讯作者：
Mayr, Florian B.